Q32 Bio: Durable Hair Regrowth Remains The Goal

Q32 Bio'S bempikibart could offer lasting hair regrowth in alopecia areata, but its potential advantage still depends on broader clinical validation.

For now, QTTB’s improved financing gives them room to maneuver in the short term, which helps de-risk the stock as well.

That means QTTB’s subsequent updates by 2H2026, 1H2027, and 2H2027 are what will ultimately make or break my bull case on the stock.

In particular, once we see QTTB’s off-treatment follow-up, we should get a better picture about bempikibart’s early responses indeed hold as expected.

Overall, I think it’s fair to reiterate my speculative “Buy” on QTTB because the upside potential is sizeable given alopecia areata’s TAM, and so far QTTB keeps making progress.

Q32 Bio Inc. (QTTB) is a small biotech working on a treatment for autoimmune hair loss that supports lasting hair regrowth.

QTTB has also recently improved its finances and is moving closer